Saudi Chemical, RDIF sign MoU to provide COVID-19 vaccine in KSA
The vaccine's manufacturing technologies will be transferred to Saudi in the second stage of the MoU
A researcher works inside a laboratory during the development of a vaccine. Image used for illustrative purpose.
By Staff Writer, Mubasher
Riyadh – Saudi Chemical Company signed a non-binding memorandum of understanding (MoU) with the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, to provide and distribute the coronavirus (COVID-19) vaccine in the kingdom.
The second stage of the one-year MoU, subject to necessary approvals from relevant bodies, stipulates the transfer of the vaccine's manufacturing technologies to the kingdom, in addition to training and qualifying national capabilities, according to a bourse filing on Tuesday.
The signing came through Saudi Chemical’s pharmaceutical sector represented in AJA Pharmaceutical Industries Co. (AJA Pharma) and Saudi International Trading Company (SITCO Pharma) with the RDIF, which had previously announced its partnership with R-Pharm company and Gamaleya research centre to produce the first Russian COVID-19 vaccine with a possibility to export it to other countries.
Moreover, the deal’s impact will reflect of Saudi Chemical's financials after the agreement completion.
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.